There are 2,864 papers on total cholesterol in aging research: 738 trials and 1,437 observational studies in people, 205 in animals, 5 in cells, 436 reviews.
2,864 papers study it435 more mention it786 findings
242 new papers in 30 daysSee all 3,299 papers on total cholesterol
At a glance
A human genetic study links higher total cholesterol with higher vascular dementia risk in people of European ancestry. Human trials report lower total cholesterol with whole grains and exercise, higher levels with low-carbohydrate or ketogenic diets, and no clear effect with some other interventions.
786 findings in 683 papers from 1989 to 2026, 127 of them since April 2026
“Some increases in triglycerides, total cholesterol, low-density lipoprotein and a decrease in high-density lipoproteins were observed in all analyzed groups.”
- Human trial738
- Humans1,437
- Animals204
- Model organisms1
- Cells5
- In silico17
Interventions
273Resveratrol
downin humans11no changein humans6upin humans5downin mice1+1
24 studies
Resveratrol
downin humans11no changein humans6upin humans5downin mice1+1
Resveratrol increases total cholesterol in humans (RSV: 9.88 mg/dL vs. ER: −13.54 mg/dL).
“Furthermore, differences between the mean changes of serum total cholesterol (RSV: 9.88 mg/dL vs. ER: −13.54 mg/dL; p < 0.001), LDL-c (RSV: 7.21 mg/dL vs. ER: −8.38 mg/dL; p = 0.006), triglycerides (RSV: 24.58 mg/dL vs. ER: −9.21 mg/dL; p = 0.048), apoB (RSV: 0.06 g/L vs. ER: −0.06 g/L; p = 0.004), and glucose (RSV: 2.54 mg/dL vs. ER: −3.08 mg/dL; p = 0.033) were observed among the RSV and ER groups”
Human trial30-daysn = 48
Molecules (Basel, Switzerland)
Resveratrol decreases total cholesterol in humans (new diagnosis of dyslipidemia) (201.4 ± 34.4 versus 220.6 ± 37.4, P = 0.04).
“individuals in the resveratrol group showed a significant decrease in total cholesterol (201.4 ± 34.4 versus 220.6 ± 37.4, P = 0.04) and triacylglycerol”
Human trialnew diagnosis of dyslipidemia100 mg/d2 mon = 71
Nutrition (Burbank, Los Angeles County, Calif.)
Resveratrol increases total cholesterol in humans (type 2 diabetes mellitus).
“Total cholesterol and triglycerides slightly increased in the Resv500arm.”
Human trialtype 2 diabetes mellitus500mg/day6 monthsn = 192
Pharmacological research
Resveratrol increases total cholesterol in humans.
“small but statistically significant increases in liver enzymes, total cholesterol, and triglycerides were observed”
Human trial4-weekn = 13
Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
Resveratrol decreases total cholesterol in patients with type 2 diabetes mellitus receiving oral hypoglycemic agents (4.70 ± 0.90 vs 4.33 ± 0.76, P < .05).
“total cholesterol (mean ± SD, 4.70 ± 0.90 vs 4.33 ± 0.76; P < .05)”
Human trialin patients with type 2 diabetes mellitus receiving oral hypoglycemic agents250 mg/d3 monthsn = 62
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Nutrition research (New York, N.Y.)
Resveratrol decreases total cholesterol in humans (overweight adults) (MD = -0.19 mmol/L, 95% CI = -0.32, -0.06).
“total cholesterol among overweight adults (MD = -0.19 mmol/L, 95% CI = -0.32, -0.06)”
Reviewoverweight adults
Nutrition journal
Resveratrol decreases total cholesterol in humans (obesity-related metabolic disorders or associated risk factors).
“Resveratrol significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol (TC)”
Reviewobesity-related metabolic disorders or associated risk factors
Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases
In vivo (Athens, Greece)
Resveratrol showed no clear effect on total cholesterol in randomized controlled trials.
“showed no significant effects on total cholesterol, low-density lipoprotein, or high-density lipoprotein”
Reviewin randomized controlled trialsn = 337
Clinical and experimental medicine
Resveratrol showed no clear effect on total cholesterol in humans (postmenopausal women) (SMD -0.09 (95% CI -0.39 to 0.22)).
“The meta-analysis on total cholesterol levels found no significant difference between groups”
Reviewpostmenopausal womenfemales
Nutrition, metabolism, and cardiovascular diseases : NMCD
Resveratrol decreases total cholesterol in humans (SMD = -0.20, 95 % CI: -0.31, -0.08; p= 0.001).
“total cholesterol (TC) (SMD = -0.20, 95 % CI: -0.31, -0.08; p= 0.001)”
Review
Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis
Prostaglandins & other lipid mediators
All 24Fewer
Berberine
downin humans11downin hamsters1no changein humans1
13 studies
Berberine
downin humans11downin hamsters1no changein humans1
Berberine decreases total cholesterol in humans (MAFLD) (p=0.0009).
“a significant divergence between the BBR and placebo groups was evident in the alteration of Δ total cholesterol (TC) p=0.0009, favoring the BBR group”
Human trialMAFLDoral1500 mg/day12 weeksn = 70
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Berberine decreases total cholesterol in overweight subjects with impaired fasting blood glucose, versus placebo (β=-0.25 (95% CI -0.45; -0.04), p=0.05).
“total cholesterol [β=-0.25, 95% C.I. (-0.45; -0.04), p=0.05]”
Human trialin overweight subjects with impaired fasting blood glucose, versus placebophytosome (phospholipid complex)2 tablets/day, 550 mg/tablettwo monthsn = 49
European review for medical and pharmacological sciences
Berberine decreases total cholesterol in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31).
“Patients who received berberine also showed statistically significant improvements in end point in body mass index (MD, -0.41; 95% CI, -0.65 to -0.17 [P = 0.001, d = 0.64]), total cholesterol (MD, -0.58; 95% CI, -0.74 to -0.41 [P < 0.001, d = 1.31]), low-density lipoprotein (MD, -0.52; 95% CI, -0.68 to -0.35 [P < 0.001, d = 1.19]), and glycated hemoglobin (MD, -0.09; 95% CI, -0.18 to 0 [P = 0.05, d = 0.37]).”
Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113
Psychiatry and clinical neurosciences
Berberine decreases total cholesterol in humans.
“After 12 weeks of intervention, men taking berberine had a larger reduction in total cholesterol and HDL-c than those taking placebo.”
Human trial12 weeksmalesn = 84
Nutrients
Berberine decreases total cholesterol in humans (-0.39 mmol/L, 95% CI -0.70 to -0.08).
“Men randomized to berberine had larger reductions in total cholesterol (-0.39 mmol/L, 95% confidence interval (CI) -0.70 to -0.08) and high-density lipoprotein cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01) after 12 weeks.”
Human trial500 mg orally, twice a day12 weeksmalesn = 80
Nutrients
Berberine decreases total cholesterol in humans (adjunctive treatment) (all p<0.05).
“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Human trialadjunctive treatment900mg/day8 weeksn = 49
Psychiatry research
Berberine decreases total cholesterol in humans (mixed dyslipidemia).
“BBR reduced TC levels.”
Human trialmixed dyslipidemiaoral500 mg t.i.d.90 daysn = 12
Journal of medicinal food
Berberine decreases total cholesterol in humans (mild hyperlipidemia).
“TG, TC, and LDL-C all decreased, and HDL-C increased in the treatment group (all P < 0.05).”
Human trialmild hyperlipidemia300 mg thrice per day3 successive months
Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
Berberine decreases total cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).
“ALT, AST, TC, TG, LDL-L, hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before”
Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Berberine showed no clear effect on total cholesterol in humans (compared to routine or statins) (SMD 0.43, 95% CI -0.39 to 1.24).
“There were no differences between berberine alone and routine or statins in improving total cholesterol (TC) (SMD, 0.43; 95% CI, -0.39 to 1.24; p = 0.30; I2 = 95%)”
Reviewcompared to routine or statins
Phytomedicine : international journal of phytotherapy and phytopharmacology
All 14Fewer
Testosterone
downin humans12
12 studies
Testosterone
downin humans12
Testosterone decreases total cholesterol in humans (compared with placebo gel in older men with low testosterone) (-6.1 mg/dL adjusted mean difference; P < 0.001).
“testosterone treatment significantly decreased total cholesterol (adjusted mean difference, -6.1 mg/dL; P < 0.001)”
Human trialcompared with placebo gel in older men with low testosteronegeladjusted to maintain the testosterone level in the normal range for young men12 monthsmales
The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials
The Journal of clinical endocrinology and metabolism
Testosterone decreases total cholesterol in humans (low-normal testosterone levels).
“Total cholesterol and HDL cholesterol decreased in the testosterone group”
Human triallow-normal testosterone levelstestosterone undecenoate80 mg twice daily6 monthsmales
Does testosterone supplementation improve health and function in elderly men?
Nature clinical practice. Endocrinology & metabolism
Testosterone decreases total cholesterol in humans (hypogonadal men with type 2 diabetes) (-0.4 +/- 0.17 mmol/l, P = 0.03).
“Total cholesterol decreased with testosterone therapy (-0.4 +/- 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed.”
Human trialhypogonadal men with type 2 diabetesi.m.200 mg every 2 weeks3 monthsmales
European journal of endocrinology
Testosterone decreases total cholesterol in hypogonadal men with ischaemic heart disease (-0.41 (0.54) mmol/l, p = 0.04).
“testosterone therapy was also associated with a significant reduction of total cholesterol and serum tumour necrosis factor alpha with delta values of -0.41 (0.54) mmol/l”
Human trialin hypogonadal men with ischaemic heart diseasea monthmalesn = 10
Heart (British Cardiac Society)
Testosterone decreases total cholesterol in humans (symptomatic androgen deficiency) (-0.25 +/- 0.4 vs. -0.004 +/- 0.4 mmol/liter, P = 0.04).
“a significant reduction in total cholesterol was recorded with testosterone therapy (-0.25 +/- 0.4 vs. -0.004 +/- 0.4 mmol/liter; P = 0.04)”
Human trialsymptomatic androgen deficiencySustanon 100serummalesn = 27
The Journal of clinical endocrinology and metabolism
Testosterone decreases total cholesterol in humans (testosterone deficiency).
“We noticed significant decrease in total cholesterol, and LDL-cholesterol.”
Human trialtestosterone deficiencytestosterone enanthate200 mg every second week1.5–6 yearsmalesn = 30
Polskie Archiwum Medycyny Wewnetrznej
Testosterone decreases total cholesterol in humans (Hypogonadism associated with aging or hypopituitarism) (Aging-associated hypogonadism: 225 ± 16.9 to 198 ± 12.8 mg/dl; hypopituitarism: 255 ± 12.1 to 206 ± 9 mg/dl at 1 year).
“through decreasing total cholesterol and atherogenic fraction of LDL-cholesterol without significant alterations in HDL-cholesterol levels or its subfractions HDL2-C and HDL3-C.”
Human trialHypogonadism associated with aging or hypopituitarismtestosterone enanthate200 mg every second week12 monthsmalesn = 22
Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
Atherosclerosis
Testosterone decreases total cholesterol in humans (WMD -10.20 mg/dL (95% CI -14.52, -5.88)).
“TRT was associated with significant reductions in total cholesterol (WMD: -10.20; 95% CI: -14.52, -5.88 mg/dL; P = 0.005)”
Reviewmales
Endocrine
Testosterone decreases total cholesterol in hypogonadal men with type 2 diabetes mellitus (WMD = -0.28 [-0.47, -0.09] p = 0.0008).
“In addition, TST can decrease cholesterol (WMD = -0.28 [-0.47, -0.09] p = 0.0008; I2 = 91%)”
Reviewin hypogonadal men with type 2 diabetes mellitusmalesn = 1,596
Diabetes & metabolic syndrome
Testosterone decreases total cholesterol in humans (late-onset hypogonadism) (MD = -0.433, 95% CI -0.761 to -0.105).
“Among the lipid profiles, total cholesterol showed significant improvement (MD = - 0.433, 95% CI - 0.761, - 0.105) after TRT.”
Reviewlate-onset hypogonadismmalesn = 1,373
International urology and nephrology
All 12Fewer
Vitamin D
downin humans7upin humans2no changein humans1
10 studies
Vitamin D
downin humans7upin humans2no changein humans1
Vitamin D decreases total cholesterol in women with PCOS.
“The BMI, WHR, insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations in women of Vitamin D group after 12 weeks of treatment were significantly lower than that in women of control group (P < 0.05).”
Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60
Journal of ovarian research
Vitamin D decreases total cholesterol in humans (subclinical hypothyroidism).
“Vitamin D supplementation significantly decreased TSH, total cholesterol, and fat mass percentage”
Human trialsubclinical hypothyroidismplasma-serum50,000 IU/week12 weeksfemalesn = 44
Frontiers in endocrinology
Vitamin D increases total cholesterol in humans (versus placebo in adults with arterial hypertension).
“Vitamin D supplementation significantly increased total cholesterol, triglycerides, very-low-density lipoprotein (VLDL) triglycerides, low-density lipoprotein (LDL) triglycerides, high-density lipoprotein (HDL) triglycerides, apolipoprotein B (ApoB)”
Human trialversus placebo in adults with arterial hypertension2800 IU daily8 weeksn = 163
Vitamin D supplementation and lipoprotein metabolism: A randomized controlled trial
Journal of clinical lipidology
Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (MD -11.69 mg/dL, 95% CI (-15.56, -7.82) mg/dL).
“total cholesterol [MD=-11.69 mg/dL, 95% CI (-15.56, -7.82) mg/dL, P < 0.00001]”
Reviewpolycystic ovary syndrome
BMC endocrine disorders
Vitamin D decreases total cholesterol in humans (SMD: - 0.14 mg/dl; 95% CI: - 0.25, - 0.02).
“Results of random effect meta-analysis indicated a significant reduction in total cholesterol (TC) (SMD: - 0.14 mg/dl; 95% CI: - 0.25, - 0.02)”
Review
Diabetology & metabolic syndrome
Vitamin D increases total cholesterol in humans (treatment duration <26 weeks) (WMD: 6.56 mg/dL, 95% CI: 0.78 to 12.35, P = 0.02).
“vitamin D increased TC when the treatment duration was ˂26 weeks (WMD: 6.56 mg/dL, 95% CI: 0.78 to 12.35, P = 0.02)”
Reviewtreatment duration <26 weeks<26 weeks
Experimental gerontology
Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (SMD: -0.36 mg/dL, 95% CI: -0.54 to -0.18 mg/dL, P<0.0001).
“reduction in total cholesterol (TC) concentrations (SMD: -0.36 mg/dL, 95% CI: -0.54 to -0.18 mg/dL, P<0.0001)”
Reviewpolycystic ovary syndrome
Annals of palliative medicine
Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (-9.09 mg/dL (95% CI: -14.90 to -3.29)).
“total cholesterol (-9.09 mg/dL; 95% CI: -14.90 to -3.29)”
Reviewpolycystic ovary syndromen = 467
The Journal of international medical research
Vitamin D decreases total cholesterol in humans (SMD -0.17 (-0.28 to -0.06)).
“total cholesterol = -0.17 (-0.28 to -0.06)”
Reviewserumn = 3,434
Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis
Nutrition reviews
Vitamin D showed no clear effect on total cholesterol in humans (1.52 mg/dl (-1.42 to 4.46 mg/dl)).
“No statistically significant effects for vitamin D supplementation were observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl)”
Review
Lipids in health and disease
Curcumin
downin humans9no changein humans1
10 studies
Curcumin
downin humans9no changein humans1
Curcumin decreases total cholesterol in humans (P = 0.015).
“total cholesterol (P = 0.015), and triglyceride (P = 0.007) compared to placebo”
Human trialcapsules500 milligram twice/dailyeight weeksfemales
Health care for women international
Curcumin decreases total cholesterol in patients with diabetes on hemodialysis (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45).
“Nanocurcumin treatment was associated with a significant reduction in triglycerides (β = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-cholesterol (β = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), total cholesterol (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05)”
Human trialin patients with diabetes on hemodialysis80 mg/d12 weeksn = 60
Iranian journal of kidney diseases
Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (β -15.86 mg/dL (95% CI, -24.48, -7.24)).
“taking curcumin was associated with a significant reduction in total cholesterol (β -15.86 mg/dL; 95% CI, -24.48, -7.24; P = 0.001)”
Human trialpolycystic ovary syndrome500 mg/day12 weeksfemalesn = 60
Clinical nutrition ESPEN
Curcumin decreases total cholesterol in humans (nonalcoholic fatty liver disease) (P < 0.001).
“Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P < 0.001)”
Human trialnonalcoholic fatty liver disease1000 mg/d8 weeksn = 87
Journal of cardiovascular pharmacology
Curcumin decreases total cholesterol in humans (NAFLD) (WMD -11.81 (95% CI -19.65 to -3.96)).
“was associated with significant reductions in levels of FBG, HOMA-IR, TG, TC, LDL, weight and BMI in patients with NAFLD.”
ReviewNAFLD50–3000 mg/day8–12 weeksn = 1,191
Complementary therapies in medicine
Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (WMD -15.591, 95% CI -27.908 to -3.273).
“total cholesterol (WMD -15.591, 95% CI -27.908 to -3.273, P = 0.013, I2 = 68.9%)”
Reviewpolycystic ovary syndrome
Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis
Frontiers in endocrinology
Curcumin decreases total cholesterol in humans (ES = -0.81 mg/dl, 95% CI: -1.39 to -0.24).
“curcumin supplementation was effective on reduction of total cholesterol (TC) (ES = -0.81 mg/dl; 95% CI: 1.39, -0.24, p = 0.006”
Review
Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis
Nutrition, metabolism, and cardiovascular diseases : NMCD
Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD = -15.55, 95% CI [-30.33, -0.76], p < .04).
“The mean difference in total cholesterol was also statistically significant (MD = -15.55; 95% CI = [-30.33, -0.76], p < .04).”
Reviewpolycystic ovary syndromen = 296
Phytotherapy research : PTR
Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD -12.45, 95% CI -22.05 to -2.85).
“It also significantly improves high-density lipoprotein (MD: 1.92, 95% CI: 0.33-3.51) and total cholesterol (MD: -12.45, 95% CI: -22.05 to -2.85).”
Reviewpolycystic ovary syndrome
Nutrients
Curcumin showed no clear effect on total cholesterol in humans (8.97 (95% CI: -4.56 to 22.51) mg/dL, p = 0.19).
“Meta-analysis of findings did not indicate a significant effect of curcumin on any of the lipid parameters.”
Review
Clinical nutrition (Edinburgh, Scotland)
Caloric restriction
downin humans5downin dogs1upin rats1downin reviews1+1
9 studies
Caloric restriction
downin humans5downin dogs1upin rats1downin reviews1+1
Caloric restriction decreases total cholesterol in humans (at 6% weight loss compared to baseline) (p = 0.04 and p = 0.008).
“The total cholesterol, triglyceride and leptin concentrations were reduced at T2 compared to T0 (p = 0.04, p = 0.008 and p = 0.02, respectively).”
Human trialat 6% weight loss compared to baseline
Physiology & behavior
Caloric restriction decreases total cholesterol in humans (combined with FATmax exercise).
“Subjects' serum TC decreased significantly”
Human trialcombined with FATmax exercise4 weeks
Frontiers in physiology
Caloric restriction decreases total cholesterol in humans.
“Adjustments for baseline values, compared with the control diet, the CRD dietary has resulted in significant reductions in TC (p = 0.028), but to a small size (ηp2 = 0.054).”
Human trialdiet4 weeksn = 90
Frontiers in nutrition
Caloric restriction decreases total cholesterol in humans (hospitalized obese women with schizophrenia) (-0.69 ± 0.70 mmol/L, p = 0.028).
“as well as total cholesterol (0.69 ± 0.70 mmol/L) with a medium effect size (p = 0.028, ηp2 = 0.054).”
Human trialhospitalized obese women with schizophrenia4 weeksfemales
Frontiers in nutrition
Caloric restriction decreases total cholesterol in humans.
“total cholesterol, LDL-cholesterol and IDL-cholesterol were significantly decreased by the calorie restriction”
Human trialsix-monthfemalesn = 60
Annals of clinical biochemistry
Caloric restriction increases total cholesterol in overweight and obese rats.
“it can significantly increase the blood concentration of TC in overweight and obese male rats.”
Animalsin overweight and obese rats40% energy restrictionmales
Scientific reports
Caloric restriction decreases total cholesterol in dogs (p < 0.0001).
“significant reductions of serum total cholesterol, glucose, alkaline phosphatase, paraxonase-1 (all p < 0.0001) and gamma-glutamyltransferase (p < 0.018) were observed in both groups, regardless of supplementation.”
Animals6 weeksn = 32
Scientific reports
Caloric restriction decreases total cholesterol.
“Fasting and caloric restriction have also been shown to beneficially influence gut microbiota composition, modify host metabolism, reduce total cholesterol and triglyceride levels”
Review
Seminars in cancer biology
Caloric restriction decreases total cholesterol in humans.
“Meta-analyses proved benefit of CR on reduction of body weight, BMI, fat mass, total cholesterol”
Review
Nutrients
Caloric restriction showed no clear effect on total cholesterol in rhesus monkeys.
“had no effect on total serum cholesterol or blood pressure.”
Animalsmalesn = 13
Mechanisms of ageing and development
Coenzyme Q10
downin humans7no changein humans2
9 studies
Coenzyme Q10
downin humans7no changein humans2
Coenzyme Q10 decreases total cholesterol in humans (type 2 diabetes mellitus) (P=0.006).
“total cholesterol (TC) (P=0.006), LDL-C (P=0.007) decreased and HDL-C (P=0.02) increased significantly in the drug group after intervention.”
Human trialtype 2 diabetes mellitusserum100 mg/day12 weeksfemales
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Coenzyme Q10 decreases total cholesterol in humans (type 2 diabetes) (P value=0.027).
“Furthermore, mean differences of TC and LDL-C level were statistically altered between two groups (P value=0.027 and 0.039 respectively).”
Human trialtype 2 diabetesdaily200 mg12 weeksn = 64
The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients
Minerva gastroenterologica e dietologica
Coenzyme Q10 decreases total cholesterol in humans (essential arterial hypertension) (from 222.9 +/- 13 mg/dl to 213.3 +/- 12 mg/dl).
“Serum total cholesterol decreased from 222.9 +/- 13 mg/dl to 213.3 +/- 12 mg/dl (P < 0.005)”
Human trialessential arterial hypertension50 mg twice daily10 weeksn = 26
Coenzyme Q10 in essential hypertension
Molecular aspects of medicine
Coenzyme Q10 decreases total cholesterol in humans (metabolic disorders) (WMD = -4.86 mg/dL, 95% CI: -8.41, -1.30).
“total cholesterol (TC, WMD = -4.86 mg/dL; 95% CI: -8.41, -1.30; p = 0.007)”
Reviewmetabolic disorders
Journal of diabetes research
Coenzyme Q10 decreases total cholesterol in humans (MD -5.53 mg/dL, 95% CI -8.40 to -2.66).
“The pooled analysis revealed that CoQ10 supplementation significantly reduced total cholesterol (TC) (MD -5.53 mg/dL; 95% CI -8.40, -2.66; I2 = 70%)”
Review
The Journal of clinical endocrinology and metabolism
Coenzyme Q10 decreases total cholesterol in humans (coronary artery disease) (SMD -1.07; 95% CI, - 1.94, - 0.21, P = 0.01).
“taking CoQ10 by patients with CAD significantly decreased total-cholesterol (SMD -1.07; 95% CI, - 1.94, - 0.21, P = 0.01)”
Reviewcoronary artery disease
Lipids in health and disease
Coenzyme Q10 showed no clear effect on total cholesterol in humans (patients with metabolic diseases) (SMD -0.07; 95% CI, -0.45, 0.31).
“CoQ10 supplementation also decreased total-cholesterol (SMD -0.07; 95% CI, -0.45, 0.31)”
Reviewpatients with metabolic diseases
Current pharmaceutical design
Coenzyme Q10 decreases total cholesterol in humans (patients diagnosed with CKD) (SMD -0.58, 95% CI -0.94 to -0.21).
“CoQ10 supplementation significantly reduced total-cholesterol (SMD=-0.58; CI, -0.94, - 0.21; P=0.002; I2: 54.9)”
Reviewpatients diagnosed with CKD
Current pharmaceutical design
Coenzyme Q10 showed no clear effect on total cholesterol in humans.
“Neither total cholesterol and cholesterol subfractions, nor triglyceride levels were affected by CoQ10 supplementation.”
Reviewn = 409
Pharmacological research
Dehydroepiandrosterone
downin humans7no changein humans1−11%
8 studies
Dehydroepiandrosterone
downin humans7no changein humans1−11%
Dehydroepiandrosterone showed no clear effect on total cholesterol in schizophrenic patients treated with olanzapine.
“There were no major changes in the overall cholesterol value, HDL cholesterol, LDL cholesterol or triglycerides in either group.”
Human trialin schizophrenic patients treated with olanzapine100 mgtwelve-weekmalesn = 45
Psychiatria polska
Dehydroepiandrosterone decreases total cholesterol in humans (hypoadrenal) (20.0 vs. -22, P = 0.02).
“DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02)”
Human trialhypoadrenaloralplasma50 mg/d3 monthsfemalesn = 33
Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women
The Journal of clinical endocrinology and metabolism
Dehydroepiandrosterone decreases total cholesterol in humans (hypoadrenal women) (P < 0.005).
“DHEA also reduced total cholesterol (P < 0.005), triglycerides (P < 0.011), LDL cholesterol (P < 0.05), and HDL cholesterol (P < 0.005).”
Human trialhypoadrenal women50-mg12 weeksfemalesn = 28
Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women
Diabetes
Dehydroepiandrosterone decreases total cholesterol in men with angiographically verified coronary heart disease, placebo-controlled crossover (222.9+/-6.6 to 207.4+/-6.6 mg/dL (p<0.05)).
“Also total cholesterol levels and LDL-cholesterol levels decreased significantly (from 222.9+/-6.6 mg/dL to 207.4+/-6.6 mg/dL and from 143.9+/-6.9 mg/dL to 130.5+/-6.0 mg/dL respectively; p<0.05).”
Human trialin men with angiographically verified coronary heart disease, placebo-controlled crossover150 mg daily40 daysmalesn = 30
Endokrynologia Polska
Dehydroepiandrosterone decreases total cholesterol in humans.
“In vivo, DHEA increased flow-mediated dilation and laser Doppler velocimetry and reduced total plasma cholesterol.”
Human trial3 monthsfemalesn = 36
The Journal of clinical endocrinology and metabolism
Dehydroepiandrosterone decreases total cholesterol in humans (Addison's disease).
“only in patients with Addison's disease a significant decrease in total cholesterol and in low-density lipoproteins after 4 months of DHEA administration was found.”
Human trialAddison's disease50 mg/day4 months
Journal of endocrinological investigation
Dehydroepiandrosterone decreases total cholesterol in humans (-11.3%).
“A marked decline of 11.3% (P less than 0.05) in serum cholesterol and 20.0% (P less than 0.05) in high density lipoprotein noted within the first week of DHEA administration”
Human trialoral1600 mg/day28 daysfemalesn = 6
The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
The Journal of clinical endocrinology and metabolism
Dehydroepiandrosterone decreases total cholesterol in humans (adrenal insufficiency).
“In adrenal insufficiency, DHEA restores DHEA/DHEAS and androstenedione levels, reduces total cholesterol, improves well-being, sexual satisfaction and insulin sensitivity”
Reviewadrenal insufficiency
Dehydroepiandrosterone (DHEA): hypes and hopes
Drugs
Levocarnitine
downin humans6no changein humans2
7 studies
Levocarnitine
downin humans6no changein humans2
Levocarnitine decreases total cholesterol in patients with chronic hepatitis C treated with interferon and ribavirin (total cholesterol 0.08 vs -0.91 mmol/l, triglycerides +0.25 vs -20 mmol/l).
“total cholesterol 0.08 vs -0.91 mmol/l (P < 0.05) and triglycerides +0.25 vs -20 mmol/l (P < 0.05)”
Human trialin patients with chronic hepatitis C treated with interferon and ribavirin2 g/day carnitine vs control12 monthsn = 70
Digestive diseases and sciences
Levocarnitine decreases total cholesterol in humans (ES = -1.05 mg/dL, 95% CI: -1.71, -0.39).
“L-carnitine supplementation significantly total cholesterol (TC) (ES = -1.05 mg/dL, 95% CI: -1.71, -0.39; p = 0.002)”
Review> 2 g/day
Frontiers in nutrition
Levocarnitine decreases total cholesterol in humans (MD = -6.45 mg dL−1, 95% CI: -9.95 to -2.95).
“TG (MD = -11.22 mg dL−1, 95% CI: -19.21 to -3.22), TC (MD = -6.45 mg dL−1, 95% CI: -9.95 to -2.95, LDLc (MD = -8.28 mg dL−1, 95% CI: -11.08 to -5.47)”
Review
Food & function
Levocarnitine decreases total cholesterol in humans (type 2 diabetes) (WMD -8.17 mg/dL, 95% CI -14.68 to -1.65).
“L-carnitine supplementation significantly reduced total cholesterol (TC) (weighted mean difference [WMD]: -8.17 mg/dL; 95% CI,-14.68 to -1.65, I2=52.2%, P = 0.041).”
Reviewtype 2 diabetes
Journal of cardiovascular and thoracic research
Levocarnitine showed no clear effect on total cholesterol in patients under hemodialysis treatment.
“Subgroup analyses showed that l-carnitine supplementation did not change TC, LDL-C and TG in patients under hemodialysis treatment.”
Reviewin patients under hemodialysis treatment
Nutrition, metabolism, and cardiovascular diseases : NMCD
Levocarnitine decreases total cholesterol in humans (MD: -8.53 mg/dl, 95% CI: -13.46, -3.6).
“meta-analysis revealed that l-carnitine supplementation significantly reduced total cholesterol (TC) (56 arms-MD: -8.53 mg/dl, 95% CI: -13.46, -3.6, I2: 93%)”
Reviewsupplementation
Nutrition, metabolism, and cardiovascular diseases : NMCD
Levocarnitine decreases total cholesterol in humans (WMD: -9.47, 95% CI: -13.23, -5.70).
“total cholesterol (WMD: -9.47; 95% CI: - 13.23, -5.70) and LDL-cholesterol (LDL-C) concentrations (WMD: -6.25; 95% CI: -9.30, -3.21)”
Review
Current pharmaceutical design
Levocarnitine showed no clear effect on total cholesterol in humans (hemodialysis patients) (SMD -0.11, 95% CI -0.31 to 0.09).
“The use of L-carnitine was not associated with a reduction in the total cholesterol (SMD, -0.11; 95% CI, -0.31 to 0.09)”
Reviewhemodialysis patients
Kidney & blood pressure research
Fish oil
no changein humans3downin humans2upin humans1downin rats1−27%
7 studies
Fish oil
no changein humans3downin humans2upin humans1downin rats1−27%
Fish oil decreases total cholesterol in humans (perimenopausal women receiving nutritional advice adapted to Mediterranean diet) (-26.86%).
“Total Cholesterol (-26,86 %; p≤0.001), Triglycerides (-25,38%; p≤0.001) and LDL-Cholesterol (-6.5 %; p≤0.01).”
Human trialperimenopausal women receiving nutritional advice adapted to Mediterranean dietfish oil1g per day60 daysfemalesn = 98
Current Women s Health Reviews
Fish oil decreases total cholesterol in humans (participants with lower adiponectin concentration at baseline).
“participants with lower adiponectin concentration showed a higher reduction of total cholesterol, LDL, LDL/high-density lipoprotein ratio, LDL/apo B, and LDL(-)”
Human trialparticipants with lower adiponectin concentration at baselineserum3 g/d2-mo
Nutrition (Burbank, Los Angeles County, Calif.)
Fish oil increases total cholesterol in apoE4 carriers relative to common E3/E3 genotype.
“In apoE4 individuals, a significant increase in total cholesterol and a trend toward a reduction in HDL-C relative to the common homozygous E3/E3 profile was evident.”
Human trialin apoE4 carriers relative to common E3/E3 genotypecapsules3.0 g eicosapentaenoic acid/docosahexaenoic acid per day6 weeksmales
ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype
Arteriosclerosis, thrombosis, and vascular biology
Fish oil showed no clear effect on total cholesterol in humans (treated hypertensives).
“there was no difference between the phases for plasma concentrations of total or high-density lipoprotein (HDL) cholesterol”
Human trialtreated hypertensivescapsules (Lipitac)plasma15 g/day8 weeksn = 20
Lack of effect of fish oil supplementation on blood pressure in treated hypertensives
Journal of hypertension
Fish oil showed no clear effect on total cholesterol in humans (mild non-insulin-dependent diabetes mellitus).
“There was no significant change in fasting plasma total, high-density lipoprotein, and low-density lipoprotein cholesterol levels.”
Human trialmild non-insulin-dependent diabetes mellitus10 g daily3 wkn = 10
Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM
Diabetes
Fish oil decreases total cholesterol in rats (significantly reduced in both fish oil groups vs corn oil groups; p < 0.001).
“The plasma's total cholesterol was significantly reduced in both FO Groups versus the CO Groups (p < 0.001)”
Animals2.8 g/kg body weight4 monthsfemales
Nutrients
Fish oil showed no clear effect on total cholesterol in humans (hyperlipidemic subjects) (-0.01 mmol/L, 95% CI: -0.03 to 0.01).
“no change in total cholesterol (-0.01 mmol/L, 95% CI: -0.03 to 0.01)”
Reviewhyperlipidemic subjects3.25 g daily
Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis
International journal of cardiology
Resistance training
downin humans5
5 studies
Resistance training
downin humans5
Resistance training decreases total cholesterol in humans.
“After 12 weeks of RT, a significant reduction was observed in adiponectin concentrations (time effect, p = 0.049; η2 = 0.131) and total cholesterol (time effect, p = 0.047; η2 = 0.134).”
Human trial12 weeksfemalesn = 30
International journal of molecular sciences
Resistance training decreases total cholesterol in humans (p < 0.05).
“CEG showed a significant reduction only in total cholesterol.”
Human trialbloodtwo monthsn = 7
Geriatrics (Basel, Switzerland)
Resistance training decreases total cholesterol in humans (271.8 ± 75.7 vs. 217.2 ± 52.2 mg/dL, p < 0.01, d = -0.8).
“Significant improvements were also found in total cholesterol (271.8 ± 75.7 vs. 217.2 ± 52.2 mg/dL; p < 0.01 and d = -0.8)”
Human trial10 weeksfemalesn = 12
Journal of bodywork and movement therapies
Resistance training decreases total cholesterol in humans (Untrained older women; change after exercise intervention).
“TC, LDL, GLU and CRP were reduced significantly (p < 0.05) after exercise intervention in the exercise group.”
Human trialUntrained older women; change after exercise interventionsingle-setSingle sets of 10–15 repetitions in 8 exercises, 3 times per week12 weeksfemales
Archives of gerontology and geriatrics
Resistance training decreases total cholesterol in humans (P < .01).
“RE significantly reduced the elevation of TC (P < .01) and LDL-C (P < .05) indices in the elderly population”
Review
Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis
Medicine
Exercise
downin humans4
4 studies
Exercise
downin humans4
Exercise decreases total cholesterol in humans (sedentary middle-aged women) (-8.2%, p < 0.001).
“Significant improvements were observed in total cholesterol (−8.2%, p < 0.001), LDL cholesterol (−11.6%, p < 0.001), HDL cholesterol (+4.1%, p < 0.001)”
Human trialsedentary middle-aged women20-weekfemalesn = 15
World Journal of Public Health
Exercise decreases total cholesterol in humans (metabolic syndrome).
“while DBP, TC, TG, and LDL-C levels were significantly improved only in the HRLAT and HALRT groups (p < 0.05).”
Human trialmetabolic syndrome12 weeksn = 85
Endocrine journal
Exercise decreases total cholesterol in humans (-26.67 mg/dL, 95% CI: -34.92, -18.42).
“Exercise significantly reduced triglycerides (TG) (-8.56 mg/dL, 95% CI: -16.72, -0.40), total cholesterol (TC)(-26.67 mg/dL, 95% CI: -34.92, -18.42)”
Reviewfemales
Journal of the International Society of Sports Nutrition
Exercise decreases total cholesterol in older adults with cognitive frailty.
“four studies showing improvements with exercise intervention via a decrease in total cholesterol, triglycerides, and low-density lipoprotein and an increase in high-density lipoprotein”
Reviewin older adults with cognitive frailty
Frontiers in physiology
Time-restricted feeding
downin humans2no changein humans1downin rats1
4 studies
Time-restricted feeding
downin humans2no changein humans1downin rats1
Time-restricted feeding decreases total cholesterol in humans.
“TRF was linked with significant reductions in triglycerides (P = 0.003) and total cholesterol (P = 0.001) levels.”
Human trial12 weeks
Research SquarePreprint
Time-restricted feeding decreases total cholesterol in diet-induced obese rats after body-weight adjustment.
“After body-weight adjustment, total cholesterol and triglycerides were reduced in fasting groups”
Animalsin diet-induced obese rats after body-weight adjustmentfour weeks
Nutrients
Time-restricted feeding decreases total cholesterol in humans (6%-7%).
“partially lower total cholesterol (6%-7%)”
Review
Frontiers in medicine
Time-restricted feeding showed no clear effect on total cholesterol in adults with overweight and obese (MD = -1.09~1.20 mg/dL, 95% CI -4.31~5.47).
“it did not alter the total cholesterol, high-density lipoprotein, and triglycerides (MDpooled = -1.09~1.20 mg/dL, 95% CI -4.31~5.47, p > 0.05)”
Reviewin adults with overweight and obesen = 1,288
Nutrients
Aerobic exercise
downin humans4
4 studies
Aerobic exercise
downin humans4
Aerobic exercise decreases total cholesterol in humans (obese postmenopausal women).
“Both exercise groups showed favourable changes in metabolic, inflammatory, and menopausal outcomes compared with the control group.”
Human trialobese postmenopausal womenthree times weeklysix weeksfemalesn = 20
Comparative Exercise Physiology
Aerobic exercise decreases total cholesterol in humans.
“The results revealed that 6 months of moderate aerobic training significantly reduced BMI, fasting blood sugar, glycosylated haemoglobin, hs-CRP, and lipid profile parameters, such as T-Cholest, TG, and LDL-C, in the patients with prediabetes (P < 0.05) group 1 and those with diabetes group 2 (P < 0.01”
Human trial6 monthsn = 58
The effects of supervised aerobic training on dyslipidaemia among diabetic older patients
BMC endocrine disorders
Aerobic exercise decreases total cholesterol in humans (-9.2% (P = 0.001)).
“significant reductions in total cholesterol (P = 0.001, -9.2%) and triglyceride (P = 0.007, -32.4%) concentrations postexercise.”
Human trial3 consecutive daysmalesn = 11
Journal of applied physiology (Bethesda, Md. : 1985)
Aerobic exercise decreases total cholesterol in humans (P < .05).
“AE significantly reduced TC (P < .05), triglycerides (P < .01), and LDL-C (P < .01), while increasing HDL-C (P < .01) in the elderly population.”
Review
Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis
Medicine
Atorvastatin
downin humans2no changein humans1no changein O. cuniculus1
4 studies
Atorvastatin
downin humans2no changein humans1no changein O. cuniculus1
Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).
“atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”
Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks
Narra X
Atorvastatin decreases total cholesterol in humans (early menopausal women with hypercholesterolemia; compared to baseline).
“both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol, triglycerides, low density cholesterol compared to baseline (all P<0.01).”
Human trialearly menopausal women with hypercholesterolemia; compared to baselineserum10 mg/d8 weeksfemales
Chinese journal of integrative medicine
Atorvastatin decreases total cholesterol in humans (decreased significantly).
“Serum total cholesterol and LDL-cholesterol levels decreased significantly.”
Human trial10 mg/day8 weeksn = 14
Journal of atherosclerosis and thrombosis
Atorvastatin showed no clear effect on total cholesterol in WHHL rabbits.
“No effect on total cholesterol, triglycerides, HDL or LDL was observed.”
Animalsin WHHL rabbits2.5 mg/kg/daymalesn = 34
Atherosclerosis
All 273Fewer
Effects
24Cognitive function
downin humans2upin humans1mediatesin humans1no changein humans1
4 studies
Cognitive function
downin humans2upin humans1mediatesin humans1no changein humans1
Total cholesterol is linked with worse cognitive function in APOE ε4 carriers (-0.020 (SD 0.009, p=0.035)).
“only in ε4 carriers that higher TC levels were significantly associated with accelerated CD, -0.020 (0.009,0.035)”
Humansin APOE ε4 carriersn = 3,496
Archives of gerontology and geriatrics
Total cholesterol is linked with worse cognitive function in CDR >= 1 group.
“associated with improved cognition in women but linked to cognitive decline in men.”
Humansin CDR >= 1 groupmalesn = 466
Aging clinical and experimental research
Total cholesterol is linked with better cognitive function in CDR >= 1 group.
“For CDR ≥ 1, TC and HDL-C were associated with improved cognition in women”
Humansin CDR >= 1 groupfemalesn = 817
Aging clinical and experimental research
Total cholesterol is linked with cognitive function in humans (mediating the APOE ε2 effect on cognition; whole sample and females).
“total cholesterol and low-density lipoprotein cholesterol mediated the protective effect of APOE ε2 on cognition in the whole sample and total cholesterol in females”
Humansmediating the APOE ε2 effect on cognition; whole sample and femalesn = 648
Sex-Specific Protective Effects of APOE ε2 on Cognitive Performance
The journals of gerontology. Series A, Biological sciences and medical sciences
Total cholesterol was not clearly linked with cognitive function in carriers of the APOE4 allele.
“No significant associations between cognitive performance and lipid profile were found for carriers of the APOE4 allele.”
Humansin carriers of the APOE4 allelen = 185
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Subarachnoid hemorrhage
no changein humans1HR 1.06
1 study
Subarachnoid hemorrhage
no changein humans1HR 1.06
Total cholesterol was not clearly linked with subarachnoid hemorrhage in humans (Genetically predicted lipid trait; analysis adjusted for lipid-lowering therapy) (HR 1.06 [0.71-1.60]).
“TC (HR 1.06 [0.71-1.60])”
HumansGenetically predicted lipid trait; analysis adjusted for lipid-lowering therapyn = 486,603
Translational stroke research
Estimated glomerular filtration rate
no changein humans1
1 study
Estimated glomerular filtration rate
no changein humans1
Total cholesterol was not clearly linked with estimated glomerular filtration rate in humans.
“No statistically significant associations were observed for total cholesterol or LDL.”
Humansn = 317
JURNAL BIOLOGI TROPIS
White matter hyperintensities
downin humans1
1 study
White matter hyperintensities
downin humans1
Total cholesterol is linked with lower white matter hyperintensities in humans (controlled total cholesterol vs uncontrolled) (0.176 vs. 0.939 mL/year).
“slower progression (e.g., controlled total cholesterol: 0.176 vs. 0.939 mL/year, p = 0.007)”
Humanscontrolled total cholesterol vs uncontrolledbrainn = 1,146
Communications medicine
Global cognition
no changein humans1
1 study
Global cognition
no changein humans1
Total cholesterol was not clearly linked with global cognition in humans after adjusting for genetic and shared environmental factors.
“In the twins modeling, after adjusting for genetic and shared environmental factors, the associations disappeared.”
Humansafter adjusting for genetic and shared environmental factors
Gerontology
Rate of brain aging
upin humans1
1 study
Rate of brain aging
upin humans1
Total cholesterol is linked with higher rate of brain aging in humans (via aorta and carotid structures).
“elevated total cholesterol level was found to accelerate brain aging by affecting the aorta and carotid structures.”
Humansvia aorta and carotid structures
Neurobiology of aging
Diastolic blood pressure
mediatesin humans1
1 study
Diastolic blood pressure
mediatesin humans1
Total cholesterol is linked with diastolic blood pressure in humans (relationship between smoking/vaping and diastolic BP) (6.7% mediation effect).
“Mediation analysis revealed that higher total cholesterol partly mediated (6.7% mediation effect) the relationship between smoking/vaping and diastolic BP.”
Humansrelationship between smoking/vaping and diastolic BPn = 6,262
American journal of physiology. Heart and circulatory physiology
Digit Symbol Coding score
no changein humans1
1 study
Digit Symbol Coding score
no changein humans1
Total cholesterol was not clearly linked with digit Symbol Coding score in air pollutant-cognition relationship (no evidence of mediation).
“there was no evidence of mediation by cholesterol levels.”
Humansin air pollutant-cognition relationshipn = 1,518
GSA 2025 abstract
Alzheimer's disease
mediatesin humans1
1 study
Alzheimer's disease
mediatesin humans1
Total cholesterol is linked with Alzheimer's disease in humans (mediating effect of BMR on Alzheimer's disease) (38.65% mediation (95% CI 15.34%–61.97%)).
“the largest contributor was total cholesterol (38.65% mediation; 95%CI 15.34%, 61.97%)”
Humansmediating effect of BMR on Alzheimer's disease
AAIC 2025 abstract
Dementia
downin humans1
1 study
Dementia
downin humans1
Total cholesterol is linked with less dementia in patients with chronic kidney disease.
“elevated LDL (>100 mg/dL), total cholesterol (≥200 mg/dL), and triglycerides (≥150 mg/dL) were protective factors”
Humansin patients with chronic kidney disease
AAIC 2025 abstract
All 24Fewer
Upstream
15Age
upin humans1downin humans1+38%
2 studies
Age
upin humans1downin humans1+38%
Age is linked with higher total cholesterol in humans (+37.8%).
“With age, plasma total cholesterol levels increased by 37.8% in men and by 34.1% in women.”
Humansmales
Siberian Journal of Life Sciences and Agriculture
Age is linked with lower total cholesterol in humans.
“we observed a decreasing trend in LnTAG (natural logarithm of Triacylglycerol) and total Cholesterol (CHR) levels with increasing age”
Humansn = 8,746
Lipids
Endotrophin
mediatesin humans1
1 study
Endotrophin
mediatesin humans1
Endotrophin mediates total cholesterol in humans (exploratory mediation analysis of the fat mass effect on total cholesterol) (15% [4, 51] of the effect mediated).
“Exploratory mediation analyses showed that endotrophin mediated 15% [4, 51] of the effect of fat mass on total cholesterol.”
Human trialexploratory mediation analysis of the fat mass effect on total cholesterol
Dynamic regulation of circulating endotrophin by changes in fat mass in humans
Metabolism: clinical and experimental
Time
downin humans1
1 study
Time
downin humans1
time is linked with lower total cholesterol in humans (-0.0027 mmol/L, p = 0.046).
“average total cholesterol decreased significantly worldwide (weighted annual change: -0.0027 mmol/L, p = 0.046)”
Humansmultidecade
Cardiology and Angiology An International Journal
Menopause
upin humans1
1 study
Menopause
upin humans1
Menopause is linked with higher total cholesterol in humans (p < 0.05).
“Postmenopausal women exhibited significantly higher TC, TG, LDL, and BMI, along with lower HDL compared to other groups (p < 0.05).”
Humansfemales
International Journal of Current Pharmaceutical Review and Research
Hypothyroidism
upin humans1
1 study
Hypothyroidism
upin humans1
Hypothyroidism is linked with higher total cholesterol in humans (compared to euthyroid controls) (p<0.05).
“Women with hypothyroidism exhibited significantly elevated levels of TC, TG, VLDL, and LDL-C along with reduced HDL-C, compared to euthyroid controls (p<0.05).”
Humanscompared to euthyroid controlsserumfemalesn = 150
Effect of hypothyroidism on lipid profile in pre- and post-menopausal women in Erbil city
Qalaai Zanist Scientific Journal
Body mass index
upin humans1
1 study
Body mass index
upin humans1
Body mass index is linked with higher total cholesterol in Chinese adults (per 1-SD body mass index increase, β-coefficient for TC: 3.43 [95% CI: 3.15-3.71] vs 2.71 [95% CI: 2.48-2.94] mg/dL).
“Obesity indicators were positively associated with elevated lipid levels (all P < 0.001)”
Humansin Chinese adultsn = 83,487
JACC. Asia
CGAS
downin mice1
1 study
CGAS
downin mice1
CGAS decreases total cholesterol in mice (shown by knockout).
“Conversely, total cholesterol levels were consistently and significantly elevated across all age groups”
Animalsshown by knockoutmales
Lifelong cGAS deficiency leads to altered lipid storage and cholesterol homeostasis
Biological research
STING1
downin mice1
1 study
STING1
downin mice1
STING1 decreases total cholesterol in mice (Healthy physiological conditions; shown by knockout compared with WT).
“STINGKO mice exhibited markedly increased circulation levels of triglycerides and total cholesterol.”
AnimalsHealthy physiological conditions; shown by knockout compared with WTblood
Biological research
SIRT1
downin humans1
1 study
SIRT1
downin humans1
SIRT1 is linked with lower total cholesterol in humans (G allele carriers) (p = 0.030).
“female carrying rs1467568 had lower levels of total cholesterol (p = 0.030), triglycerides (p = 0.026) and LDL cholesterol (p = 0.013).”
HumansG allele carriersfemalesn = 405
Frontiers in genetics
8-iso-PGF2α
mediatesin humans1
1 study
8-iso-PGF2α
mediatesin humans1
8-iso-PGF2α is linked with total cholesterol in humans (36.63%).
“Mediation analyses verified that 8-iso-PGF2α partially mediated the correlations between blood As with TC (36.63%) and LDL-C (34.03%).”
Humansserumn = 360
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
All 15Fewer
Associations
210Mortality
downin humans4upin humans3HR 0.67–8.68
7 studies
Mortality
downin humans4upin humans3HR 0.67–8.68
Total cholesterol is linked with a lower risk of mortality in humans (HR 0.993, 95% CI 0.986-1.000).
“total cholesterol (P=0.003, HR=0.969, 95% CI=0.949-0.989 and P=0.046, HR=0.993, 95% CI=0.986-1.000, respectively) showed a decreased risk of mortality”
Humans596±44 daysn = 112
Minerva cardiology and angiology
Total cholesterol is associated with mortality in humans (Chinese participants; multivariable Cox regression) (HR 0.88, 95% CI 0.78–1.00).
“In oldest old aged 85 and older, serum total cholesterol levels are inversely associated with all-cause mortality.”
HumansChinese participants; multivariable Cox regressionserum3 yearsn = 903
Frontiers in endocrinology
Total cholesterol is linked with a lower risk of mortality in humans (geriatric patients with hip fractures) (HR = 0.67, 95% CI: 0.53-0.85).
“Linear multivariate Cox regression models showed that TC levels were associated with mortality (hazard ratio (HR) = 0.67; 95% confidence interval (95% CI): 0.53-0.85; p = 0.001 after adjusting for confounding factors).”
Humansgeriatric patients with hip fracturesn = 339
Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Total cholesterol is associated with mortality in humans (men not on statin therapy, adjusted for comorbidities; per 1 mmol/L decrease) (HR 1.22, 95% CI 1.03 to 1.44).
“and mortality (HR 1.22, 95% CI 1.03 to 1.44, p=0.02) adjusted for comorbidities”
Humansmen not on statin therapy, adjusted for comorbidities; per 1 mmol/L decreaseper 1 mmol/L decreasemean follow-up 6.4±2.7 yearsmalesn = 731
Heart (British Cardiac Society)
Total cholesterol is associated with mortality in humans (Borderline-high total cholesterol (5.18–6.21 mmol/l) versus <5.18 mmol/l) (HR 0.71, 95% CI 0.61–0.83).
“borderline-high (5.18-6.21 mmol/l) and high (≥6.22 mmol/l) total cholesterol were associated with a decreased risk of all-cause mortality”
HumansBorderline-high total cholesterol (5.18–6.21 mmol/l) versus <5.18 mmol/lMedian follow-up 7.5 years63.7% womensn = 3,090
BMC geriatrics
Total cholesterol is associated with mortality in humans (statin-treated) (HR 1.53, 95% CI 1.43-1.64).
“Compared with TC values of 4.5-5.4 mmol/L, TC values <3.0 mmol/L were associated with higher mortality (statin treated hazard ratios 1.53, 95% confidence interval 1.43-1.64, p < .001”
Humansstatin-treatedn = 99,758
The journals of gerontology. Series A, Biological sciences and medical sciences
Total cholesterol is associated with mortality in humans (Lowest quartile: HR 8.68, 95% CI 2.14-35.21).
“the lowest quartile of total cholesterol showed independent association with mortality (HR 8.68, CI 2.14-35.21, p<0.01).”
HumansPrevalent peritoneal dialysis patients; lowest quartile of total cholesterol; adjusted analysis36 monthsn = 106
Nutritional predictors of mortality in prevalent peritoneal dialysis patients
Acta biochimica Polonica
Alzheimer's disease
upin humans5downin humans1OR 0.867–2.5
6 studies
Alzheimer's disease
upin humans5downin humans1OR 0.867–2.5
Total cholesterol is associated with Alzheimer's disease in humans.
“higher total cholesterol and type 2 diabetes were associated with lower and higher AD risk, respectively, in males.”
HumansGenetically predicted total cholesterol; Mendelian randomization with inconsistent sensitivity-analysis supportmales
Sex differences in genetic liability to modifiable Alzheimer's disease risk factors
medRxivPreprint
Total cholesterol is associated with Alzheimer's disease in humans (Genetically predicted total cholesterol).
“Total cholesterol (TC) was positively associated with Alzheimer disease (AD) and dementia.”
HumansGenetically predicted total cholesterol
Cholesterol links to dementia varied by genetic region
Genes
Total cholesterol is linked with a higher risk of Alzheimer's disease in humans (Mendelian randomization; verbal risk direction conflicts with the reported odds ratio) (OR 0.867, 95% CI 0.776–0.968; P = .011).
“Higher levels of total cholesterol (OR: 0.867, 95% CI: 0.776-0.968, P = .011), triglycerides (OR:0.870, 95% CI: 0.767-0.985, P = .028) were connected to increased AD risk.”
HumansMendelian randomization; verbal risk direction conflicts with the reported odds ratio
Medicine
Total cholesterol is associated with Alzheimer's disease in humans (lowest VIM quintile of total cholesterol) (OR 2.5 (1.5-4.0)).
“the lowest VIM quintile of total cholesterol [odds ratio: 2.5(1.5-4.0: P < 0.001)]”
Humanslowest VIM quintile of total cholesterolblood
Lipid trajectories improve risk models for Alzheimer's disease and mild cognitive impairment
Journal of lipid research
Total cholesterol is associated with Alzheimer's disease in humans.
“elevated fasting insulin and total cholesterol levels were associated with an increased risk of dementia in Alzheimer's disease”
Humans
Impact of diabetes mellitus on the risk of Alzheimer's disease: a mendelian randomization study
BMC neurology
Total cholesterol is associated with Alzheimer's disease in humans (OR 1.21 per mg/dL greater total cholesterol, 95% CI 1.09–54.05).
“1.21 for AD (1.09-54.05)”
HumansMendelian randomization using APOE as a genetic instrument; APOE4+ compared with APOE3 carriersn = 1,534
Journal of Alzheimer's disease : JAD
Alzheimer's disease is associated with total cholesterol in humans (Compared with cognitively normal controls).
“Those with AD and late MCI (ps < 0.001) had higher total cholesterol than the control group.”
HumansCompared with cognitively normal controls
Journal of Alzheimer's disease : JAD
Dementia
upin humans3downin humans3OR 0.674
6 studies
Dementia
upin humans3downin humans3OR 0.674
Total cholesterol is associated with dementia in humans (heterogeneous community of older adults) (r = -0.244, p = 0.029).
“total cholesterol levels showed a significant negative correlation with dementia risk (r = -0.244; p = 0.029)”
Humansheterogeneous community of older adultsn = 80
Jurnal Pinang Masak
Total cholesterol is linked with a higher risk of dementia in humans (univariable Mendelian randomization, inverse variance weighting).
“Elevated total cholesterol (TC) increased dementia, ADD, and DLB.”
Humansunivariable Mendelian randomization, inverse variance weighting
Statins cut Alzheimer's risk but raise other dementia risks
Journal of Alzheimer's disease reports
Total cholesterol is associated with dementia in humans.
“We observed a weaker association between total cholesterol and dementia incidence”
Humansn = 1,853,954
The lancet. Healthy longevity
Total cholesterol is linked with a lower risk of dementia in humans (OR 0.674, p = .005).
“total cholesterol (TC) (OR: 0.674, p = .005) was a protective factor for dementia”
Humans
Brain and behavior
Total cholesterol is associated with dementia in humans (HR=4.21; 95% CI 1.28 to 13.85).
“Among men only, TC decline from first visit was significantly associated with increased dementia risk (HR=4.21; 95% CI 1.28 to 13.85).”
Humansmedian time of around 25 yearsmales
Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment
Journal of epidemiology and community health
Total cholesterol is associated with dementia in humans.
“A decline in serum total cholesterol levels may be associated with early stages in the development of dementia.”
Humans26 yearsmales
Archives of neurology
Dementia is associated with total cholesterol in humans.
“Cholesterol levels in men with dementia and, in particular, those with Alzheimer disease had declined at least 15 years before the diagnosis”
Humans26 yearsmales
Archives of neurology
Menopause
upin humans6
6 studies
Menopause
upin humans6
Menopause is associated with total cholesterol in post-menopausal compared to pre-menopausal women.
“There is statistically significant raised values of TC, TAG and LDL-c values were observed among post-menopausal participants”
Humansin post-menopausal compared to pre-menopausal womenfemalesn = 100
Association of Atherogenic Index Among Postmenopausal Bangladeshi Women
Journal of Netrokona Medical College
Menopause is associated with total cholesterol in humans (menopause transition and postmenopause).
“whereas CHOL and LDLC levels were higher in both the menopause transition and postmenopause stages.”
Humansmenopause transition and postmenopausefemales
Frontiers in endocrinology
Menopause is associated with total cholesterol in humans (Postmenopausal compared with premenopausal women).
“Post-menopausal women demonstrated significantly elevated total cholesterol, triglycerides, LDL-C, Non-HDL cholesterol, AIP, CRI-I, and CRI-II compared to pre-menopausal controls (p<0.001).”
HumansPostmenopausal compared with premenopausal womenfemales
TAJ Journal of Teachers Association
menopause is associated with total cholesterol in humans (menopausal transition, compared with matched men) (+16.7 vs -3.1 mg/dL in women versus men).
“Compared with the men, the women showed a greater increase in serum total cholesterol (+16.7 vs -3.1 mg/dL, P < 0.001)”
Humansmenopausal transition, compared with matched men3 to 6 years before and after menopause agefemalesn = 263
Menopause (New York, N.Y.)
Menopause is associated with total cholesterol in humans (adjusted for confounders) (0.2 to 0.4 mmol/L higher TC, 0.1 to 0.3 mmol/L higher LDL-c).
“At all ages between 46 and 55 years, and after adjustment for confounders, naturally postmenopausal women had 0.2 to 0.4 mmol/L higher TC and 0.1 to 0.3 mmol/L higher LDL-c levels compared to premenopausal women in the same age range.”
Humansadjusted for confoundersfemales
BMC medicine
Menopause is associated with total cholesterol in humans.
“Independent of aging, menopausal status is associated with elevations in serum total cholesterol, LDL cholesterol, apolipoproteins, and triglycerides, and decreases in HDL cholesterol (HDL-C).”
Reviewfemales
Dyslipidemia in midlife women: Approach and considerations during the menopausal transition
Maturitas
Age
upin humans3downin humans1mixedin humans1
5 studies
Age
upin humans3downin humans1mixedin humans1
Age is associated with total cholesterol in humans (PMOS).
“The 30s group had significantly higher total cholesterol and glycated hemoglobin levels than the <30 group”
HumansPMOS
Journal of clinical medicine
Age is associated with total cholesterol in humans (p < 0.001).
“age and BMI were significant in influencing the level of total cholesterol (p < 0.001)”
Humans
Kesmas Indonesia
Age is associated with total cholesterol in humans among Africans (p=0.035, 44.4% of >50 yrs had levels <100 mg/dL).
“TC decreased significantly with age in Africans (p=0.035): 44.4% of >50 yrs had levels <100 mg/dL.”
Humansamong Africansn = 112
AHA Scientific Sessions 2025 abstract
Age is associated with total cholesterol in humans.
“Total cholesterol and LDL-cholesterol concentrations increased with age, which became attenuated between the early 30s and late 50s in men, and declined thereafter.”
Humansmales
PloS one
Age is associated with total cholesterol in humans (lifetime multivariate analysis) (P = 6.9 × 10−4, 9.3 % of variance).
“Total cholesterol was associated positively with multivariate age only (P = 6.9 × 10−4, 9.3 % of variance).”
Humanslifetime multivariate analysisplasma-serumfemalesn = 120
Endocrine
Postmenopausal status
upin humans4
4 studies
Postmenopausal status
upin humans4
Postmenopausal status is associated with total cholesterol in humans (Natural menopause) (Postmenopausal TC: 205 mg/dL).
“Postmenopausal status was independently associated with higher TC (205 mg/dL), LDL-C (119 mg/dL), HDL-C (62 mg/dL), and TG (106 mg/dL) (all p < 0.001)”
HumansNatural menopausefemalesn = 2,098
AHA Scientific Sessions 2026 abstract
Postmenopausal status is associated with total cholesterol in humans (postmenopausal versus premenopausal women).
“Result shows significantly higher total cholesterol (TC), triglycerides (TG), VLDL, LDL of postmenopausal women when compared with premenopausal women”
Humanspostmenopausal versus premenopausal womenfemales
African Journal of Allied Health Sciences (AJAHS)
Postmenopausal status is associated with total cholesterol in humans (Women with obesity; postmenopausal versus premenopausal groups) (Total cholesterol: 235.76 ± 28.78 versus 204.94 ± 46.99 mg/dL; LDL: 131.61 ± 43.20 versus 107.35 ± 25.37 mg/dL).
“Statistical analysis showed significant differences in total cholesterol and LDL levels between the groups of postmenopausal and premenopausal women with obesity.”
HumansWomen with obesity; postmenopausal versus premenopausal groupsfemalesn = 80
Jurnal Ners
Postmenopausal status is associated with total cholesterol in humans (Postmenopausal compared with premenopausal Saudi women).
“Postmenopausal women exhibited significantly higher levels of total cholesterol (TC), triglycerides (TG), Ca, and PTH, and lower HDL-C and Vit-D levels compared to premenopausal women”
HumansPostmenopausal compared with premenopausal Saudi womenserumfemalesn = 300
Medicine
APOE
upin humans4
4 studies
APOE
upin humans4
APOE is associated with total cholesterol in humans across lifestyles.
“having more APOE ε4 alleles is associated with higher total cholesterol, higher LDL cholesterol, and lower HDL cholesterol.”
Humansacross lifestyles
PLoS genetics
APOE is associated with total cholesterol in the subjects with high serum tHcy level (p < 0.05).
“ApoE rs429358 and rs7412 variants were observed to have the highest serum TC and TG level in the subjects with high serum tHcy level (p < 0.05).”
Humansin the subjects with high serum tHcy levelblood
BMC psychiatry
APOE is associated with total cholesterol in humans (APOE4+ compared with APOE3 and APOE2+ carriers).
“Total cholesterol was higher in APOE4+ compared to APOE3 and APOE2+ (ps < 0.04) carriers.”
HumansAPOE4+ compared with APOE3 and APOE2+ carriersn = 1,534
Journal of Alzheimer's disease : JAD
APOE is associated with total cholesterol in humans (APOE4 carriers among Tsimane forager-farmers of Bolivia).
“APOE4 is associated with 30% lower C-reactive protein, and higher total cholesterol and oxidized LDL.”
HumansAPOE4 carriers among Tsimane forager-farmers of Bolivia50% femalesn = 1,266
eLife
Cognitive function
upin humans4
4 studies
Cognitive function
upin humans4
Total cholesterol is associated with cognitive function in humans.
“total cholesterol exhibited a weak positive correlation with the ACE-III score”
Humans
The Role of Laboratory Parameters and Neuropsychological Assessment in Preventive Primary Care
Preprints.orgPreprint
Total cholesterol is associated with cognitive function in humans (p < 0.05).
“TC levels were positively associated with MMSE (p < 0.05).”
Humans
MedComm
Total cholesterol is associated with cognitive function in humans.
“The level of total cholesterol and moderate alcohol consumption had positive relationship with CF indices in women”
Humansfemales
Advances in gerontology = Uspekhi gerontologii
Total cholesterol is associated with cognitive function in humans (rG = 0.33).
“positive genetic correlations between cognition and total cholesterol (rG = 0.33)”
Humans
Geriatrics & gerontology international
Cardiovascular disease
upin humans2upin silico1
3 studies
Cardiovascular disease
upin humans2upin silico1
Total cholesterol is associated with cardiovascular disease in humans (Offspring of coronary heart disease patients; elevated total cholesterol).
“elevated LDL-C and CHOL levels increased the risk of CVD.”
HumansOffspring of coronary heart disease patients; elevated total cholesterol3 monthsn = 88
BMC cardiovascular disorders
Cardiovascular disease is associated with total cholesterol in humans (postmenopausal women) (207.7 ± 20.4 mg/dl vs 173.8 ± 21.0 mg/dl).
“Mean Cholesterol levels were significantly increased in the CVD group compared to controls (207.7 ± 20.4mg\dl vs control 173.8 ± 21.0 mg\dl).”
Humanspostmenopausal womenbloodfemales
Tikrit Journal of Pharmaceutical Sciences
Total cholesterol predicts cardiovascular disease in silico.
“SHAP analysis revealed the relative importance of predictors, with age, TC and Digit Symbol Score (DSS) ranking highest.”
In silicon = 4,713
Improving 10-year cardiovascular disease risk prediction using automated machine learning
International journal of cardiology
Coronary artery disease
upin humans3OR 4.3
3 studies
Coronary artery disease
upin humans3OR 4.3
Total cholesterol is linked with a higher risk of coronary artery disease in adults with metabolic syndrome (aOR 3.65, 95% CI 1.13~11.78).
“Total cholesterol levels of 200-239 mg/dL were associated with 3.65 times higher odds (95% CI = 1.13~11.78).”
Humansin adults with metabolic syndrome200-239 mg/dL
Journal of Korean biological nursing science
Total cholesterol is linked with a higher risk of coronary artery disease in humans (hypertension).
“Advanced age, smoking, hypertension duration >10 years, and abnormal total cholesterol (TC) were independently associated with an increased risk of CHD in elderly hypertensive patients.”
Humanshypertensionn = 428
Predictive value of lipid levels in coronary heart disease in elderly hypertensive patients
American journal of translational research
Total cholesterol is linked with a higher risk of coronary artery disease in humans (OR 4.30 [2.41-7.65]).
“Patients in the highest versus the lowest TC-category of the HS had an OR of 4.30 [2.41-7.65] for significant CAD at angiography”
Humans
Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk
EBioMedicine
Estimated glomerular filtration rate
upin humans1downin humans1
2 studies
Estimated glomerular filtration rate
upin humans1downin humans1
Total cholesterol is associated with estimated glomerular filtration rate in humans (healthy, sedentary) (R = -0.512 to -0.582, p < 0.05).
“There was a negative correlation between blood total cholesterol vs. eGFR (R = -0.512, R = -0.582, R = -0.531; p < 0.05)”
Human trialhealthy, sedentaryn = 18
Diseases (Basel, Switzerland)
Total cholesterol is associated with estimated glomerular filtration rate in humans (elderly individuals at nursing home).
“There was a significant correlation between total cholesterol and LDL with eGFR (positive)”
Humanselderly individuals at nursing homen = 76
Ebers Papyrus
Ceramide
upin humans1
1 study
Ceramide
upin humans1
Total cholesterol is associated with ceramide in humans (adhering to a healthy dietary pattern) (13 ceramide species).
“total cholesterol revealed a marked positive correlation with 13 ceramide species”
Human trialadhering to a healthy dietary pattern15 g daily16-weekn = 41
Frontiers in nutrition
Total cholesterol is associated with ceramide in humans.
“Among the remaining serum lipoproteins, positive associations were prominent between TC and Cer (n = 13), PC (n = 5), and SM (n = 3); LDL-C and Cer (n = 3) as well as HDL-C and PC (n = 10), Cer (n = 3), and SM (n = 2).”
Humans16-weekn = 41
Frontiers in nutrition
Multicomponent training combined with nutritional education and psychoeducation
downin humans1
1 study
Multicomponent training combined with nutritional education and psychoeducation
downin humans1
Multicomponent training combined with nutritional education and psychoeducation is associated with total cholesterol in humans (hypercholesterolemia; no nonintervention control group).
“Total cholesterol and LDL-c decreased at all follow-up assessments in the hypercholesterolemic group”
Human trialhypercholesterolemia; no nonintervention control groupthree weekly sessions12, 24, and 36 weeksfemalesn = 16
Journal of clinical medicine
More on Multicomponent training combined with nutritional education and psychoeducation
Rehabilitation exercise training
downin humans1
1 study
Rehabilitation exercise training
downin humans1
Rehabilitation exercise training is associated with total cholesterol in humans (p < 0.001).
“comprising decreases in CRP, total cholesterol, aHSG/fetuin-A, and GDF-15 and an increase in IGF-1 (all p < 0.001).”
Human trialFollowing hip or knee arthroplasty; unadjusted within-participant comparison without a concurrent control groupindividualizedserum21 daysn = 42
Biomedicines
Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate
downin humans1
1 study
Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate
downin humans1
Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate is associated with total cholesterol in humans (borderline hyperlipidemia).
“TC and LDL-C were significantly negatively correlated with phosphatidylserine (PS), phosphatidylcholine (PC), and bis(monoacylglycerol)phosphate (BMP).”
Human trialborderline hyperlipidemiaerythrocyte membrane
Food & function
More on Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate
All 210Fewer
How this record changed
Summary rewritten as its findings changed.
As it read before
Lower total cholesterol is linked with higher mortality in peritoneal dialysis patients. Human trials report decreases with whole grains, aerobic exercise and resistance training in untrained older women, but increases with low-carbohydrate and ketogenic diets; resveratrol results point both ways. A behavior-tailored intervention shows no clear effect compared with usual care.
Summary rewritten as its findings changed.
As it read before
Human observational studies link total cholesterol to memory function in APOE4 noncarriers and the rate of processing-speed decline in carriers. Trials report decreases with whole grains, caloric restriction and aerobic exercise, increases with ketogenic or low-carbohydrate diets, and no change with a behavior-tailored intervention compared with usual care.
Summary rewritten as its findings changed.
As it read before
Human studies associate total cholesterol with brain aging, epigenetic age acceleration and cognition, and with coronary artery disease in adults with metabolic syndrome. Human trials report reductions with berberine and, in older women, resistance training, but increases with ketogenic versus low-fat, moderate-carbohydrate diets and with filtered Arabica–Robusta coffee. A quercetin trial reports no change.
Summary rewritten as its findings changed.
As it read before
Human studies associate total cholesterol with dementia in opposing directions, including lower risk in people with chronic kidney disease, and with higher coronary disease risk. A study in people of European ancestry reports no association with cognitive status. Human trials report cholesterol reductions with multidomain lifestyle interventions and a calorie-restricted DASH diet in sedentary older adults with obesity.
Summary rewritten as its findings changed.
As it read before
Human trials report lower total cholesterol with whole grains, plant protein, dietary counseling and multidomain lifestyle intervention. A sustainable healthy diet trial reports a reduction in metabolic phenotype 1 but no change in phenotype 3. Human studies associate total cholesterol with higher coronary artery disease risk in adults with metabolic syndrome and higher dementia risk.